TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02431494

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue light phototherapy
Description: Blue light phototherapy (BLU-U Blue Light Photodynamic Therapy Illuminator manufactured by DUSA Pharmaceutical Inc. Wilmington, MA) At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes. The duration of each session will be approximately 20 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcurrent therapy
Description: Microcurrent therapy (Micro Current Electro-Device w/gloves and carrying case, SKU:DSE-X1008 Classic Spa Collection) The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated. The duration of each session will be approximately 45 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combination of BLP and Microcurrent
Description: Same devices as described above. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
Study: NCT02329262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring to be Active with Accelerometers
Description: Trained high school mentors will deliver a 10 session curriculum targeting physical activity to younger teens.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Planning to be Active with Accelerometers
Description: Health education teachers will deliver the 10 session curriculum targeting physical activity to high school students enrolled in health courses.
Study: NCT03117296

Intervention type: OTHER
Intervention: Post procedure daily PT and OT
Description: PT evaluation and treatment on post procedure day zero: Nurses mobility patient using egress testing one time

Intervention type: OTHER
Intervention: PT post procedure
Description: post procedure day one: PT and OT assessment, education and intervention.

Intervention type: OTHER
Intervention: OT post procedure
Description: PT and OT Daily until goals met or patient discharge.

Intervention type: OTHER
Intervention: Routine PT or OT
Description: Routine PT or OT consulted by physician when identified discharge disposition of home
Study: NCT01044485

Intervention type: DRUG
Group type: OTHER
Intervention: lapatinib
Description: escalation dose from 1250 to 1500 mg in association with docetaxel

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Description: escalation dose from 75 mg/m2 to 100 mg/m2 in association with lapatinib
Study: NCT03305263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: One tablet a day from inclusion until end of pregnancy or gestational age 28

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine placebo
Description: One tablet a day from inclusion until end of pregnancy or gestational age 28
Study: NCT04094103

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active strawberry powder
Description: Participants will drink a strawberry beverage with active ingredients once a day during the 4-week intervention period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo strawberry powder
Description: Participants will drink a strawberry placebo beverage once a day during the 4-week intervention period.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mixed strawberry powder
Description: Participants will drink a mixed strawberry beverage with active ingredients and placebo once a day during the 4-week intervention period.
Study: NCT00053963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV
Study: NCT04609917

Intervention type: PROCEDURE
Intervention: trainee invlovement
Description: Patients underwent selective biliary cannulation with trainee involvement
Study: NCT04979377

Intervention type: OTHER
Intervention: Clinical hyperandrogenism assessment
Description: Modified Ferriman-Gallwey scale

Intervention type: DIAGNOSTIC_TEST
Intervention: Total testosterone (ng/dL)
Description: Circulating total testosterone (LC-MS/MS or IQL-CDC method) at follicular phase

Intervention type: DIAGNOSTIC_TEST
Intervention: A1c (%)
Description: High Performance Liquid Chromatography (HPLC)

Intervention type: DIAGNOSTIC_TEST
Intervention: Total cholesterol
Description: Determined by enzymatic methods

Intervention type: OTHER
Intervention: Body mass index (BMI) (kg/m2)
Description: Defined as body weight divided by the square of body height, and expressed in kg/m2

Intervention type: DIAGNOSTIC_TEST
Intervention: Frequency of chronic vascular complications [n (%)]
Description: Retinopathy, nephropathy, neuropathy, and macrovascular disease.

Intervention type: DIAGNOSTIC_TEST
Intervention: Polycystic ovary morphology
Description: Sonographic assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular autonomic reflex tests (CARTs)
Description: Cardioautonomic function assessement by Vital scan HW7-HW6T:

Intervention type: DIAGNOSTIC_TEST
Intervention: Sex hormone-binding globulin (SHBG) (nmol/L)
Description: Circulating SHBG (IQL) at follicular phase

Intervention type: DIAGNOSTIC_TEST
Intervention: Dehydroepiandrosterone-sulphate (IQL) (ng/mL)
Description: Circulating DHEAS (IQL) at follicular phase

Intervention type: OTHER
Intervention: Waist circumference (cm)
Description: Waist circumference measurement made at the top of the iliac crest

Intervention type: OTHER
Intervention: Waist-to-hip ratio
Description: Waist circumference divided by hip circumference (measurement should be taken around the widest portion of the buttocks)

Intervention type: OTHER
Intervention: Body composition
Description: Vital Scan HW7-HW6T

Intervention type: DIAGNOSTIC_TEST
Intervention: Mean glucose (mg/dL)
Description: Continuous glucose monitoring (GCM) records

Intervention type: DIAGNOSTIC_TEST
Intervention: Time in target range (hours)
Description: Continuous glucose monitoring (GCM) records

Intervention type: DIAGNOSTIC_TEST
Intervention: Time in hyperglycemia (hours)
Description: Continuous glucose monitoring (GCM) records

Intervention type: OTHER
Intervention: Insulin dose (UI/Kg)
Description: Daily insulin dose divided by body weight

Intervention type: OTHER
Intervention: Insulin sensitivity
Description: Equation that relies on routine clinical measures: A1c, presence of hypertension, and waist circumference

Intervention type: DIAGNOSTIC_TEST
Intervention: High-density lipoprotein (HDL) (mg/dL)
Description: Enzymatic methods after precipitation of serum with phosphotungstic acid and Mg2+

Intervention type: DIAGNOSTIC_TEST
Intervention: Low-density lipoprotein (LDL) (mg/dL)
Description: Estimated by the Friedewald's equation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Triglycerides (mg/dL)
Description: Determined by enzymatic methods
Study: NCT02715271

Intervention type: PROCEDURE
Intervention: therapeutical surgery for TB
Description: Patients undergoing therapeutical surgery for tuberculosis (DS- and MDR/XDR-TB) indicated as per clinical routine

Intervention type: PROCEDURE
Intervention: therapeutical surgery for TB
Description: Patients undergoing therapeutical surgery for tuberculosis (DS- and MDR/XDR-TB) indicated as per clinical routine
Study: NCT02149992

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: myo-inositol
Description: myo-inositol, oral, 2g, twice a day for 5 days total
Study: NCT00898807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram
Description: target dose 30mg daily for 9 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily for 9 weeks
Study: NCT02149992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring surveillance
Description: monitoring device will be placed by experienced research members to the patient on Day 1 and she will continue to wear until Day 7. This device monitors overall glycemia every 5 minutes and records the information, which can be downloaded after discontinued.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose monitoring
Description: patients will use the glucose meter, test strips, and lancets to determine her capillary glucose levels 4 times per day (fasting, and 1 hour post-prandial levels)
Study: NCT00213239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
Study: NCT02601144

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation
Study: NCT02974244

Intervention type: DRUG
Intervention: exenatide once weekly
Description: exenatide treatment in the customary clinical care in the USA

Intervention type: DRUG
Intervention: basal insulin
Description: basal insulin treatment in the customary clinical care in USA
Study: NCT02103842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Study: NCT01548235

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Prescribed biphasic insulin aspart 30 as part of routine care. Starting dose, dose titration and injection frequency determined individually by each physician.
Study: NCT04067999

Intervention type: DRUG
Intervention: Semaglutide
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
Study: NCT01461551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: anesthesia was maintained with sevoflurane (end-tidal concentration 1.0-1.5 minimum alveolar concentration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: anesthesia was maintained with propofol (2-4 μg/ml via target-controlled infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combine of sevoflurane and propofol
Description: anesthesia was maintained with a combine of propofol (1 μg/ml via target-controlled infusion) and sevoflurane (end-tidal concentration 0.7-1.0 minimum alveolar concentration)
Study: NCT00733434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Description: PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
Study: NCT04472689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: patients will receive a loading dose of IV lidocaine 1.5mg/kg slowly diluted with 20 ml normal saline just before induction of anesthesia, then the lidocaine infusion started at a rate of 2mg/kg/h diluted in normal saline by rate of 2 ml/ kg/h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: patients will receive an equal volume of normal saline (both the loading, and the infusion). The infusion in both groups will be started just after induction of anesthesia induction, and continued until the end of the operation
Study: NCT03815175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE
Description: Subjects who received XIENCE family stent systems will be included.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT (aspirin and/or P2Y12 receptor inhibitor)
Description: 1-month clear subjects (pooled from Xience 28 USA study and Xience 28 Global study) will receive 1 month of DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for \> 7 consecutive days and will discontinue P2Y12 receptor inhibitor as early as 28 days and will continue with aspirin monotherapy through 12-month follow-up.
Study: NCT04178148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amikacin dose optimization
Description: Therapeutic drug optimization of amikacin using the BestDose software algorithm
Study: NCT00866437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin test panel
Description: Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1mmol/L~3. Estrone 3mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)
Study: NCT03797729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive Tirofiban(0.05mg/ml) intravenous drip in a dosage of 4ml/hour (patients weight\<50kg) or 6ml/hour (patients weight \> 50kg) lasting for 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive normal saline intravenous drip in a dosage of 4ml/hour (patients weight\<50kg) or 6ml/hour (patients weight \> 50kg) lasting for 24 hours.
Study: NCT03273972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Informed Consent
Description: To be completed prior to conducting any study related procedures

Intervention type: OTHER
Group type: OTHER
Intervention: Written Informed Consent
Description: To be completed prior to conducting any study related procedures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inclusion/Exclusion check
Description: Eligibility check
Study: NCT00866437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin test panel
Description: Hormones:~1. Progesterone 1mmol/L~2. Estradiol 1 mmol/L~3. Estrone 3 mmol/L~4. Estriol 3mmol/l~   Controls:~5. Saline (NaCl) 0.9%~6. Ethyl Oleate with 10% Benzyl Alcohol~7. Histamine phosphate 1mg/ml (epicutaneous- prick test)
Study: NCT00779168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: white button mushroom extract
Description: For this dose escalation study 6 patients will be treated at each of the following dosages: 4 grams PO daily, 6 grams PO daily, 8 grams PO daily, 10 grams PO daily, 12 grams PO daily and 14 grams PO daily.
Study: NCT03273972

Intervention type: OTHER
Group type: OTHER
Intervention: Inclusion/Exclusion check
Description: Eligibility check

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full Clinical Chemistry and Haematology Bloods
Description: Participant required to fast for at least 6-8 hoursprior to visit. (Clear, non-caffeinated fluids are allowed)

Intervention type: OTHER
Group type: OTHER
Intervention: Full Clinical Chemistry and Haematology Bloods
Description: Participant required to fast for at least 6-8 hoursprior to visit. (Clear, non-caffeinated fluids are allowed)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum sample for systemic markers and lipid sub-fractions
Description: Serum samples may be stored for later analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: Serum sample for systemic markers and lipid sub-fractions
Description: Serum samples may be stored for later analysis.
Study: NCT02688023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1
Description: The regimen consisted of irinotecan 150mg/m2 administered as an intravenous infusion on day 1, oxaliplatin 85 mg/m2 administered intravenously on day 2, leucovorin 200 mg intravenously on day 2, 5-fluorouracil 500 mg administered by intravenous bolus,followed by 2400 mg/m2 by 44 h continuous intravenous infusion starting on day 2. S-1 (40-60mg orally twice per day for 10 days) or capecitabine (1000mg/m2 orally twice per day for 10 days) can be substituted for intravenous 5-fluorouracil.14 days as a cycle, up to 4 cycles.
Study: NCT01559428

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant sterol-enriched margarine
Description: Daily consumption of 20 gram of a plant sterol-enriched margarine (providing daily 3.0 gram of plant sterols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant sterol-enriched margarine is consumed together with a high-fat milkshake
Study: NCT00779168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Immune cell subset number will be evaluated by flow cytometry on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
Study: NCT01559428

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant stanol-enriched margarine
Description: Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control margarine
Description: Daily consumption of 20 gram of a control margarine, for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the control margarine is consumed together with a high-fat milkshake
Study: NCT00779168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Testing will be performed on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Performed on blood samples collected pre-study (within 4 weeks of registration) and during weeks 3, 5, 9, 13, every 4 weeks beyond week 13 and at off study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gas chromatography-mass spectrometry
Description: Gas Chromatography-Mass Spectrometry (GC-MS) will be used to evaluate C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Evaluation of C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
Study: NCT03273972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pregnancy Test
Description: If applicable for women of child bearing potential

Intervention type: OTHER
Group type: OTHER
Intervention: Pregnancy Test
Description: If applicable for women of child bearing potential
Study: NCT03840291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban will be used for resolution of left atrial appendage thrombi
Study: NCT02777372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline will be provided at a dose of 50 mg daily for up to 3 weeks, depending on the length of a woman's luteal phase. Medication will be taken only during the luteal phase. Women will initiate sertraline treatment upon determining that they have ovulated (using a urine luteinizing hormone (LH) Kit) and remain on sertraline until onset of their next menstrual period at which time they will stop taking the medication.
Study: NCT00834067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moexipril HCl/hydrochlorothiazide 15/25 mg tablets
Description: 1 x 15/25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UNIRETIC® 15/25 mg tablets
Description: 1 x 15/25 mg
Study: NCT00426621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Gel
Description: 4 grams per knee, 4 times per day, for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 grams per knee, 4 times per day, for 12 weeks
Study: NCT01250912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123I-metaiodobenzylguanidine
Description: FDA Approved for use in Cancer patients. This use is Off Label. For the imaging study, an activity of 370 MBq (10 mCi) 123I-mIBG (GE Healthcare) will be administered intravenously, and a 10-minute planar image of the anterior thorax (128_128 matrix) will be acquired beginning 15 minutes after tracer injection.
Study: NCT03801980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-1403
Description: Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
Study: NCT01116362

Intervention type: PROCEDURE
Group type: OTHER
Intervention: primary repair
Description: during the first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: secondary repair
Description: after one week,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
Study: NCT03359356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: A total of 24 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 24 doses